Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F16IL2 and BI 836858 in Relapsed AML Post-AlloHSCT
NCT03207191Phase 1Completed
- Sponsor
- Philogen
- Start
- Dec 2016
- Primary completion
- Mar 2020
- Modality
- Antibody Fragments, Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of teleukin and BI 836858 in acute myeloid leukemia (AML), sponsored by Philogen. Primary endpoint: Dose-Limiting Toxicities. Started Dec 2016; status: completed.
02
Drugs
teleukinBI 836858
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03207191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03207191.